Radiation, Durvalumab, and Chemo Improve Survival in ES-SCLC
Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.
Adding low-dose radiotherapy to standard-of-care durvalumab and chemotherapy led to survival benefits among patients with extensive-stage small cell lung cancer.
The requirement of large-scale expensive cancer screening trials spanning decades creates considerable barriers to the development, commercialisation, and implementation of novel screening tests. One way…
Caribbean small island developing states are becoming increasingly vulnerable to compounding disasters, prominently featuring climate-related hazards and pandemic diseases, which exacerbate existing barriers to cancer…
The purpose of this European Society for Radiotherapy and Oncology (ESTRO) project, endorsed by the European Association of Urology, is to explore expert opinion on…
On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) fo
Here, we summarize results from a phase II trial assessing the safety and efficacy of camrelizumab in combination with GEMOX followed by auto-HSCT in patients…
Frontline eftilagimod alpha plus pembrolizumab generated responses in patients with recurrent or metastatic HNSCC with negative PD-L1 expression.
Aasma Shauka, MD, MPH, New York University, New York, NY, discusses the current landscape of colonoscopy screening in the United States. Colonoscopy is the primary…
Vol. 21 Issue 12 p3304 – 3316 Nicola J. Mutch Robert L. Medcalf Fibrinolysis is the system primarily responsible for removal of fibrin deposits and…
Overall, GHS and quality of life were maintained for both treatment groups, with prespecified PRO variables favouring trastuzumab deruxtecan over treatment of physician’s choice, suggesting…
The addition of durvalumab to gemcitabine and cisplatin did not have a detrimental effect on patient-reported outcomes. These results suggest that durvalumab, gemcitabine, and cisplatin…